Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001697884-22-000018

← back to feed
Filed
Dec 21, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Oct 31, 2022 206.52M sh
Cash And Equivalents Q3 2023 · Oct 31, 2022 $24.05K
Cash And Equivalents Q3 2023 · Jan 31, 2022 $107.21K
Cash And Equivalents Q3 2023 · Oct 31, 2021 $214.06K
Cash And Equivalents Q3 2023 · Jan 31, 2021 $45.4K
Current Liabilities Q3 2023 · Oct 31, 2022 $473.59K
Current Liabilities Q3 2023 · Jan 31, 2022 $1.74M
Total Liabilities Q3 2023 · Oct 31, 2022 $761.79K
Total Liabilities Q3 2023 · Jan 31, 2022 $2.03M
Current Assets Q3 2023 · Oct 31, 2022 $2.05M
Current Assets Q3 2023 · Jan 31, 2022 $3.06M
Total Assets Q3 2023 · Oct 31, 2022 $2.44M
Total Assets Q3 2023 · Jan 31, 2022 $3.6M
Operating Cash Flow Q3 2023 · Oct 31, 2021 −$241.66K
Sga Expense Q3 2023 · Oct 31, 2021 $157.45K
Sga Expense Q3 2023 · Oct 31, 2021 $308.17K
Operating Income Q3 2023 · Oct 31, 2021 $137.45K
Operating Income Q3 2023 · Oct 31, 2021 −$292.83K
Gross Profit Q3 2023 · Oct 31, 2021 $20K
Gross Profit Q3 2023 · Oct 31, 2021 $601K
Cost Of Revenue Q3 2023 · Oct 31, 2021 $180K
Cost Of Revenue Q3 2023 · Oct 31, 2021 $1.52M
Revenue restated Q3 2023 · Oct 31, 2021 $200K
Revenue Q3 2023 · Oct 31, 2021 $2.12M